By Benjamin Chiou
Date: Monday 02 Jun 2025
(Sharecast News) - Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary listing to the Nasdaq.
The company, which in May 2024 said it would stay listed in London "for as long as it is considered to be in the best...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news